Ford (F) stock falls 2% after the automaker files recalls for 2.4M vehicles with NHTSA over rearview camera and windshield wiper issues in 2026. The post Ford (Ford (F) stock falls 2% after the automaker files recalls for 2.4M vehicles with NHTSA over rearview camera and windshield wiper issues in 2026. The post Ford (

Ford (F) Stock Slides 2% Following Massive 2.4M Vehicle Recall Announcement

2026/03/06 23:58
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Key Takeaways

  • Ford disclosed approximately 2.4 million vehicle recalls through six distinct filings on Tuesday.
  • Primary concerns involve defective rearview cameras and malfunctioning windshield wipers.
  • Shares of Ford traded down 2.1% to $12.08 during Friday’s early session.
  • Warranty expenses at Ford reached nearly 5% of revenue in 2025, exceeding GM’s approximately 4%.
  • Year-to-date in 2026, Ford has issued 17 recall actions impacting 7.3 million vehicles.

Ford Motor has expanded its 2026 recall tally significantly, submitting six new actions to the National Highway Traffic Safety Administration on Tuesday that affect close to 2.4 million vehicles.


F Stock Card
Ford Motor Company, F

The bulk of these recalls center on two primary defects: faulty rearview camera systems and windshield wiper failures. Most remedies involve software patches or component inspections performed at authorized dealerships.

The most extensive individual recall encompasses approximately 889,950 units. Models affected include 2020–2022 Ford Escape and Lincoln Corsair variants, plus 2020–2024 Lincoln Aviator and Explorer models experiencing rearview camera images that flip or invert when drivers shift into reverse.

Another substantial recall impacts 849,310 vehicles, specifically certain 2021–2026 Ford Bronco units and 2021–2024 Ford Edge models. These vehicles suffer from rearview cameras that may completely fail to display an image — presenting obvious safety concerns.

Ford’s stock price declined 2.1% to $12.08 during Friday morning trading. However, broader market weakness contributed to the selloff, with the S&P 500 losing 1.4% and the Dow dropping 1.6% amid disappointing employment data and climbing crude oil prices.

The automaker’s shares have already retreated approximately 8% year-to-date, making Friday’s decline another setback in a challenging period.

Warranty Expense Scrutiny Intensifies

While recalls typically don’t trigger sustained stock declines, they contribute directly to warranty liabilities, where investor attention has intensified.

Ford’s warranty-related costs — including reserves adjusted for existing warranties — approached 5% of total sales during 2025. This figure surpasses competitor General Motors (GM), whose warranty expenses hovered around 4%.

Through 2026 to date, Ford has initiated 17 separate recall campaigns covering 7.3 million vehicles. By comparison, the entire 2025 calendar year saw 220 recalls affecting 17.7 million vehicles industrywide. The current year’s trajectory is raising eyebrows among market observers.

Ford Defends Aggressive Recall Strategy

The company’s position is that identifying and addressing defects proactively — even when affecting large vehicle populations — proves more beneficial than allowing problems to escalate into costlier warranty obligations down the road.

Whether investors accept this rationale depends largely on tangible improvements in quality metrics and a downward trajectory in warranty expenditures over subsequent quarters.

Ford’s complete 2026 warranty cost data will ultimately determine whether this proactive recall philosophy delivers financial benefits or remains a drag on profitability.

The post Ford (F) Stock Slides 2% Following Massive 2.4M Vehicle Recall Announcement appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09